MedTrace Logo

Pentriox - Induction of Oxidative Stress

NCT02188472 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2014-07-11

No results posted yet for this study

Summary

The purpose of the study is to investigate phenoxymethylpenicillin (the v-penicillin) and trimethoprim's possible induction of oxidative stress in human cells. The induction is examined by comparing changes in oxidative stress in the treatment group with the change in a placebo group. The study is a randomized-based placebo-controlled study. Each treatment group consists of 30 healthy male volunteers who consume either v-penicillins, trimethoprim or placebo over 7 days. The induction of oxidative stress is measured by 8-oxoguanosine and 8-oxodeoxoguanosine, isolated from urine. A t-test will be performed to compare drug treatment with placebo. The results will be published.

Conditions

  • Oxidative Stress

Interventions

DRUG

Penicillin V

Penicillin V: 2 x 330mg tablets should be taken twice daily

DRUG

Trimethoprim

Trimopan: 2 x 100mg tablets should be taken twice daily

DRUG

Placebo

Placebo: 2 tablets should be taken twice daily

Sponsors & Collaborators

  • Klinisk Biokemisk Afdeling

    collaborator UNKNOWN

  • Klinisk farmakologisk Afdeling

    collaborator UNKNOWN

  • Sektion for Biomedicin Institut for Veterinær Patobiologi

    collaborator UNKNOWN

  • Henrik Enghusen Poulsen

    lead OTHER

Principal Investigators

  • Henrik E Poulsen, MD · Department head

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02188472 on ClinicalTrials.gov